新兵中的耐多药结核病
Multidrug-resistant tuberculosis in military recruits.
作者信息
Freier Grace, Wright Allen, Nelson Gregory, Brenner Eric, Mase Sundari, Tasker Sybil, Matthews Karen L, Bohnker Bruce K
机构信息
Naval Hospital Beaufort-Branch Medical Clinic, Parris Island, South Carolina, USA.
出版信息
Emerg Infect Dis. 2006 May;12(5):760-2. doi: 10.3201/eid1205.050708.
Abstract
We conducted a tuberculosis contact investigation for a female military recruit with an unreported history of multidrug-resistant tuberculosis (MDRTB) and subsequent recurrence. Pertinent issues included identification of likely contacts from separate training phases, uncertainty on latent MDRTB infection treatment regimens and side effects, and subsequent dispersal of the contacts after exposure.
摘要
我们对一名有未报告的耐多药结核病（MDRTB）病史及后续复发情况的女性新兵进行了结核病接触者调查。相关问题包括确定来自不同训练阶段的可能接触者、潜伏性MDRTB感染治疗方案及副作用的不确定性，以及接触者在暴露后的后续分散情况。
相似文献
1
Multidrug-resistant tuberculosis in military recruits.
Emerg Infect Dis. 2006 May;12(5):760-2. doi: 10.3201/eid1205.050708.
2
Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2.
3
Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
Pediatrics. 2009 Mar;123(3):902-3. doi: 10.1542/peds.2008-2664.
4
[Reasons for drug-resistant tuberculosis emergence].
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Jun;30(6):403-5.
5
[Pulmonary tuberculosis caused by Mycobacterium bovis with primary resistance to Isoniazide and pyrazinamide].
An Med Interna. 1997 Aug;14(8):433-4.
6
Drug-resistant tuberculosis among previously treated patients in Yangon, Myanmar.
Int J Mycobacteriol. 2016 Sep;5(3):366-367. doi: 10.1016/j.ijmyco.2016.06.004. Epub 2016 Jun 23.
7
[The clinical features of tuberculosis in children and adolescents excreting drug-resistant Mycobacterium tuberculosis strains].
Probl Tuberk Bolezn Legk. 2009(6):13-6.
8
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Int J Tuberc Lung Dis. 2002 Dec;6(12):1102-9.
9
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2011 Oct;15(10):1331-3. doi: 10.5588/ijtld.11.0098.
10
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Int J Tuberc Lung Dis. 2002 Nov;6(11):952-8.
引用本文的文献
1
Tuberculosis in Adolescents and Young Adults: Emerging Data on TB Transmission and Prevention among Vulnerable Young People.
Trop Med Infect Dis. 2021 Aug 5;6(3):148. doi: 10.3390/tropicalmed6030148.
2
Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Clin Infect Dis. 2017 Jun 15;64(12):1670-1677. doi: 10.1093/cid/cix208.
3
Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
Int J Tuberc Lung Dis. 2014 Aug;18(8):912-8. doi: 10.5588/ijtld.13.0028.
本文引用的文献
1
Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC.
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):1-47.
2
Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America.
MMWR Recomm Rep. 2005 Nov 4;54(RR-12):1-81.
3
Update on the treatment of tuberculosis and latent tuberculosis infection.
JAMA. 2005 Jun 8;293(22):2776-84. doi: 10.1001/jama.293.22.2776.
4
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8. doi: 10.1128/AAC.48.4.1281-1288.2004.
5
Treatment of tuberculosis.
MMWR Recomm Rep. 2003 Jun 20;52(RR-11):1-77.
6
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
CMAJ. 2002 Jul 23;167(2):131-6.
7
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5. doi: 10.1128/AAC.46.4.1022-1025.2002.
8
Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.
MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51.
9
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95. doi: 10.1164/ajrccm.161.4.16141.
10
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Clin Infect Dis. 1997 Jun;24(6):1264-5. doi: 10.1093/clinids/24.6.1264.
Zotero 插件